Allakos Inc. operates as a clinical stage bio-technology company. The Company discovers and develops therapeutic antibodies for the treatment of allergic, inflammatory, and proliferative diseases. Allakos serves customers in the United States.

Current Report (Form 8-K | Period ending 2025-05-15)

Quarterly Report (Form 10-Q | Period ending 2025-03-31)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Allakos Inc (ALLK US)

Current Report (Form 8-K | Period ending 2025-05-15)

Quarterly Report (Form 10-Q | Period ending 2025-03-31)

Annual Report (Amendment) (Form 10-K/A | Period ending 2024-12-31)

SC14D9C | Written communication by the subject company relating to a third party tender offer

Current Report (Form 8-K | Period ending 2025-04-01)

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)